作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Correlation of CD117 and DOG1 Expression with the Clinicopathological Features and Prognosis in Triple-negative Breast Cancer
-
摘要: 目的 探究CD117、DOG1表达水平与三阴性乳腺癌triple-negative breast cancer，TNBC）患者临床病理特征及预后的相关性。 方法 回顾性纳入2000-2011年北京协和医院TNBC患者。取其肿瘤组织芯片，采用免疫组化法检测肿瘤细胞中CD117、DOG1表达情况，分析二者与患者年龄、肿瘤直径、美国癌症联合会American Joint Committee on Cancer，AJCC）癌症分期、组织学分级、P53、Ki-67增殖指数等临床病理特征的关系，及其对患者生存期的影响。 结果 共入选符合纳入与排除标准的TNBC患者185例，其中CD117阳性24例12.97%），DOG1阳性22例11.89%），二者共表达率为1.62%。相较于肿瘤细胞CD117阴性患者，CD117阳性患者中高Ki-67增殖指数87.50%比67.70%，P=0.048）、基底样TNBC95.83%比74.53%，P=0.020）、P53弥漫强阳33.33%比13.66%，P=0.032）的比例均更高。相较于DOG1阴性患者，DOG1阳性患者中肿瘤直径≤2cm 22.73%比45.40%，P=0.026）、基底样TNBC 54.55%比80.37%，P=0.015）的比例均更低。中位随访时间71个月范围：2~170个月），失访4例2.16%），复发或远处转移66例35.68%），死亡34例18.38%）。生存分析显示，AJCC分期HR=7.624，95% CI：2.187~26.576，P=0.001）及CD117阳性伴P53弥漫强阳HR=3.942，95% CI：1.366~11.379，P=0.011）与TNBC患者总生存期呈负相关。 结论 CD117阳性、DOG1阴性与基底样TNBC具有一定相关性，且CD117阳性伴P53弥漫强阳者总生存期更短，死亡风险增高。Abstract: Objective To investigate the expression of CD117 and DOG1 in triple negative breast cancer (TNBC) and to explore their relationship with clinicopathologic features and prognosis. Methods The patients with TNBC in Peking Union Medical College Hospital from 2000 to 2011 were retrospectively collected and tissue microarrays were made. The expression of CD117 and DOG1 in tumor cells was detected by immunohistochemistry to analyze their relationship with the clinicopathological characteristics of the patients, such as age, tumor diameter, American Joint Committee on Cancer (AJCC) cancer stage, histological grade, P53, and Ki-67 proliferation index, and explore the effect of both on the survival of patients. Results A total of 185 TNBC patients meeting the inclusion and exclusion criteria were selected, of which 24 (12.97%) were CD117 positive and 22 (11.89%) were DOG1 positive, with a co-expression rate of 1.62%. Compared with CD117-negative patients, CD117-positive patients had higher Ki-67 proliferation index (87.50% vs. 67.70%, P=0.048), basal-like TNBC (95.83% vs. 74.53%, P=0.020), and P53 diffuse positive (33.33% vs. 13.66%, P=0.032). Compared with DOG1-negative patients, DOG1-positive patients had lower proportions of tumor diameter ≤ 2cm (22.73% vs. 45.40%, P=0.026) and basal-like TNBC (54.55% vs. 80.37%, P=0.015). The median follow-up was 71 months (range:2-170 months), 4 cases (2.16%) were lost to follow-up, 66 cases (35.68%) relapsed or had distant metastasis, and 34 cases (18.38%) died. Survival analysis showed that AJCC stage (HR=7.624, 95%CI:2.187-26.576, P=0.001) and CD117 positive with P53 diffuse strong positive (HR=3.942, 95%CI:1.366-11.379, P=0.011) were negatively correlated with the overall survival of TNBC patients. Conclusion The expression of CD117 and DOG1 were significantly related to basal-like TNBC, CD117 positive with P53 diffuse strong positive may be correlated with a shorter overall survival and a higher mortality risk.
-
Key words:
- triple-negative breast cancer /
- CD117 /
- DOG1 /
- prognosis
-
[1] Borri F, Granaglia A. Pathology of triple negative breast cancer[J]. Semin Cancer Biol, 2021, 72:136-145. [2] Funkhouser A T, Strigenz A M, Blair B B, et al. KIT mutations correlate with higher galectin levels and brain metastasis in breast and non-small cell lung cancer[J]. Cancers (Basel), 2022, 14(11):2781. [3] Roskoski R, Jr. Properties of FDA-approved small molecule protein kinase inhibitors:a 2023 update[J]. Pharmacol Res, 2023, 187:106552. [4] Luo Y L, Huang W T, Zhang H Z, et al. Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer[J]. Oncol Lett, 2018, 15(5):6161-6170. [5] Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity[J]. Science, 2008, 322(5901):590-594. [6] Bae J S, Park J Y, Park S H, et al. Expression of ANO1/DOG1 is associated with shorter survival and progression of breast carcinomas[J]. Oncotarget, 2017, 9(1):607-621. [7] Jansen K, Farahi N, Büscheck F, et al. DOG1 expression is common in human tumors:a tissue microarray study on more than 15,000 tissue samples[J]. Pathol Res Pract, 2021, 228:153663. [8] Nielsen T O, Leung S C Y, Rimm D L, et al. Assessment of Ki67 in breast cancer:updated recommendations from the international Ki67 in breast cancer working group[J]. J Natl Cancer Inst, 2021, 113(7):808-819. [9] Rakha E A, Ellis I O. Triple-negative/basal-like breast cancer:review[J]. Pathology, 2009, 41(1):40-47. [10] Sheikh E, Tran T, Vranic S, et al. Role and significance of c-KIT receptor tyrosine kinase in cancer:a review[J]. Bosn J Basic Med Sci, 2022, 22(5):683-698. [11] Nielsen T O, Hsu F D, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10(16):5367-5374. [12] Schulmeyer C E, Fasching P A, Häberle L, et al. Expression of the immunohistochemical markers CK5, CD117, and EGFR in molecular subtypes of breast cancer correlated with prognosis[J]. Diagnostics (Basel), 2023, 13(3):372. [13] Kriegsmann K, Flechtenmacher C, Heil J, et al. Immunohistological expression of SOX-10 in triple-negative breast cancer:a descriptive analysis of 113 samples[J]. Int J Mol Sci, 2020, 21(17):6407. [14] Mitri Z I, Abuhadra N, Goodyear S M, et al. Impact of TP53 mutations in triple negative breast cancer[J]. NPJ Precis Oncol, 2022, 6(1):64. [15] Pan Y B, Yuan Y F, Liu G S, et al. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients[J]. PLoS One, 2017, 12(2):e0172324. [16] Jansson S, Bendahl P O, Grabau D A, et al. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer[J]. PLoS One, 2014, 9(7):e102176. -
点击查看大图
计量
- 文章访问数: 9
- HTML全文浏览量: 3
- PDF下载量: 1
- 被引次数: 0
下载:
